Company intelligence / Profile preview

Revel Pharmaceuticals

San Francisco, California, United Statesrevelpharmaceuticals.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Revel is developing therapeutic enzymes to break down glucosepane and other AGE crosslinks. They are preparing to move into pilot studies in animal models and human cadaver tissue from biobanks.

Therapeutic areas: CardiovascularNephrologyRheumatologyEndocrinologyDermatology
Modalities: Therapeutic enzymesdrugssmall molecules
Industry: Biotech

Beyond the preview

Go deeper on Revel Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Revel Pharmaceuticals.

Explore the full profile